Yahoo
NasdaqGS - Nasdaq Real Time Price USD

Adaptive Biotechnologies Corporation (ADPT)

24.89 -1.75 (-6.57%)
As of 3:38:19 PM EST. Market Open.
Trade ADPT on Coinbase
ADPT Q3 2026 earnings call
November 4, 2026 at 4:30 PM EST
Chart Range Bar
Loading chart for ADPT
  • Previous Close 26.64
  • Open 26.98
  • Bid 19.30 x 200
  • Ask 32.06 x 200
  • Day's Range 24.80 - 27.44
  • 52 Week Range 12.00 - 30.74
  • Volume 1,625,067
  • Avg. Volume 2,170,970
  • Market Cap (intraday) 3.972B
  • Beta (5Y Monthly) 2.15
  • PE Ratio (TTM) --
  • EPS (TTM) -0.41
  • Earnings Date Nov 4, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 30.21
  • Zacks Rating Neutral

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

www.adaptivebiotech.com

624

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Performance Overview

Trailing total returns as of 11/2/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

ADPT
53.26%
S&P 500 (^GSPC)
10.30%

1-Year Return

ADPT
43.38%
S&P 500 (^GSPC)
10.39%

3-Year Return

ADPT
412.14%
S&P 500 (^GSPC)
74.88%

5-Year Return

ADPT
27.94%
S&P 500 (^GSPC)
63.06%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue 70.87M
Earnings -20.03M
Profit Margin -28.27%

Q2

FY25

Q3

FY25

Q4

FY25

Q1

FY26

-20M
0
20M
40M
60M
80M
-40.0%
-30.0%
-20.0%
-10.0%
0.0%
10.0%

Analyst Insights

View More

Analyst Price Targets

21.00 Low
30.21 Average
24.89 Current
35.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 10/13/2026
Analyst TD Cowen
Rating Action Maintains
Rating Buy
Price Action Raises
Price Target 28 -> 32

Statistics

View More

Valuation Measures

Annual
As of 10/30/2026
  • Market Cap

    4.25B

  • Enterprise Value

    4.33B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (current)

    --

  • Price/Sales (ttm)

    13.42

  • Price/Book (mrq)

    29.65

  • Enterprise Value/Revenue

    14.04

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -20.73%

  • Return on Assets (ttm)

    -4.12%

  • Return on Equity (ttm)

    -38.76%

  • Revenue (ttm)

    308.08M

  • Net Income Avi to Common (ttm)

    -63.85M

  • Diluted EPS (ttm)

    -0.41

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    344.26M

  • Total Debt/Equity (mrq)

    272.46%

  • Levered Free Cash Flow (ttm)

    18.98M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

24.89 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: